Chasing 40% Weight Loss May Cost Muscle and Metabolic Health, Experts Warn

Why this matters: GLP-1 receptor agonists have evolved into dual and triple agonists and combination regimens, pushing weight-loss benchmarks toward 30-40% of body mass, a range once achievable only with bariatric surgery. This perspective from Molecules and Cells argues that the metric has become decoupled from the real goal of metabolic health, with commercial competition shaping clinical expectations.

What the authors examine: This is a narrative perspective rather than a systematic review or original study, so there are no new methods or datasets. The authors illustrate their argument with market events. In December 2024, Novo Nordisk shares fell by up to 26% (settling near 20%) after CagriSema produced 22.7% weight loss in REDEFINE 1, short of the 25% the company had signaled. On February 23, 2026, REDEFINE 4 showed CagriSema at 23.0% (adherent) and 20.2% (intent-to-treat), versus 25.5% and 23.6% for tirzepatide. The authors report a 15.1% share drop and about $100 billion in lost market value for Novo Nordisk.

Key arguments: Weight loss of 5-10% improves blood pressure and glycemia for most people, while 15% or more is often needed for type 2 diabetes remission and meaningful MASH improvement. These are specialized needs, not universal targets. BMI also fails to separate lean from fat mass. East Asians typically carry 3-5% more body fat at the same BMI and often develop metabolic disease at BMIs Western standards call normal, so for someone with a BMI of 24 the authors suggest a 30% loss could cause severe sarcopenia, while a targeted 3-5% reduction of visceral and ectopic fat might address the underlying problem. They also describe mechanisms by which aggressive therapy may harm muscle. Appetite suppression can mask the hypothalamic starvation signal from falling leptin. Visceral fat-derived inflammation may raise myostatin (up to 100-fold in a mouse study). Strong glucagon suppression may impair hepatic amino acid clearance, and together with low protein intake this could drive muscle proteolysis, which the authors call iatrogenic undernutrition. In SUSTAIN 8, over 40% of the weight lost was fat-free mass.

Implications and emerging responses: Muscle-sparing agents are in development. Bimagrumab added to semaglutide produced 22.1% weight loss with about 93% from fat in a phase II trial, and Regeneron's COURAGE trial reported up to 80% less lean mass loss with trevogrumab and garetosmab. Weight regain is a further concern. A BMJ meta-analysis cited by the authors found regain of about 0.8 kg per month after stopping semaglutide or tirzepatide, with blood pressure, cholesterol, and HbA1c returning to baseline within roughly 12-14 months. The authors also raise a hypothesis that β-arrestin-sparing biased agonists (orforglipron, CT-868, PF-08653944) may cause prolonged receptor activation and amplify neurodevelopmental and psychiatric risks, especially as use extends to younger patients.

Caveats: The piece is opinion-based, selectively cites evidence, and several claims (biased agonism risks, East Asian sarcopenia from large weight loss, mouse-derived myostatin effects) are mechanistic or extrapolated rather than demonstrated in outcome trials. The authors propose individualized targets focused on visceral and organ fat, but offer no tested framework for doing so.